Tag: biomarker clinical phase outsourcing services market drivers

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the biomarker clinical phase outsourcing services market size evolved in recent years?

The biomarker clinical phase outsourcing services market has seen exponential growth in recent years. It is expected to rise from $9.71 billion in 2024 to $11.94 billion in 2025, at a CAGR of 23.0%. This growth is attributed to government initiatives and funding, increased use of biomarkers in diagnostics, more R&D funding, technological advancements in genomics and imaging, and the rising demand for cancer biomarkers.

What are the predictions for the biomarker clinical phase outsourcing services market size in the coming years?

The biomarker clinical phase outsourcing services market is forecast to grow exponentially, reaching $27.09 billion by 2029, with a CAGR of 22.7%. This growth is driven by the expanding use of biomarkers in clinical trials, increasing demand for precision medicine, companion diagnostics adoption, and rising demand for personalized medicine. Key trends include advanced trial parameters, diagnostic-focused clinical phases, biomarker technology advancements, government funding, and tech advancements.

Get your biomarker clinical phase outsourcing services market report here!

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

What key factors are fueling the growth of the biomarker clinical phase outsourcing services market?

The rising number of clinical trials is likely to fuel the biomarker clinical phase outsourcing services market. Clinical trials, which test new treatments or procedures on human participants, have surged due to advancements in medical research, a rise in chronic diseases, and increased funding. Outsourcing providers bring specialized knowledge in biomarker discovery and analysis, enhancing the quality of clinical trial data. In May 2023, the United States National Library of Medicine reported a growth in registered clinical trials, increasing from 399,499 in 2022 to 437,533 across 221 countries. Consequently, the increase in clinical trials is supporting the biomarker clinical phase outsourcing services market.

How is the global biomarker clinical phase outsourcing services market divided into key segments?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

Who are the key firms paving the way for growth in the biomarker clinical phase outsourcing services market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC

Which trends are expected to transform the biomarker clinical phase outsourcing services market?

Leading companies in biomarker clinical phase outsourcing services are enhancing their competitive position by advancing high-throughput flow cytometry and ELISpot testing for more accurate and rapid biomarker analysis. In November 2022, Celerion Inc., a US-based biotechnology outsourcing services company, expanded its offerings to include GLP/GCP-compliant molecular and cell biology testing. This expansion improves Celerion’s ability to support clients through all stages of drug development, from early clinical research to regulatory submissions, allowing for the production of high-quality data that meets regulatory standards and accelerates new medicine development.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15740

What regions are contributing significantly to the growth of the biomarker clinical phase outsourcing services market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2023. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Bioanalytical Testing Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioanalytical-testing-services-global-market-report

Single-Use Bio Reactors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/singleuse-bioreactors-global-market-report

Bioadhesives Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioadhesives-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Biomarker Clinical Phase Outsourcing Services Market, and How Will It Perform by 2034?

The market size of outsourcing services for clinical phases of biomarkers has seen substantial expansion in the previous years. The market which was valued at $9.71 billion in 2024, is expected to reach up to $11.94 billion in 2025, implying a compound annual growth rate (CAGR) of 23.0%. Various factors like increased governmental initiatives and funding, a surge in the diagnostic utilization of biomarkers, a growth in R&D financial support from the government, rapid progress seen in technological landscapes like genomics, proteomics, and imaging, as well as a rising demand for cancer biomarkers, have notably contributed to this historic period’s growth.

The market size of biomarker clinical phase outsourcing services is predicted to undergo a significant surge in the coming years. The market is projected to reach a valuation of $27.09 billion by 2029, with a compound annual growth rate (CAGR) of 22.7%. The growth forecasted for this period is attributed to the escalating utilization of biomarkers across various stages of clinical trials. There is a broadening scope of biomarker use in clinical trials, which is further influenced by an increased demand for precision medicines, a heightened rate of companion diagnostics adoption, and a growing preference for personalized medicine. Several trends forecasted for this period include advancements in trial parameters, a focus on diagnostic-related clinical phases, quick progression in biomarker technology, an incline in government initiatives and funding, and the evolution in technology.

What External and Internal Drivers Are Contributing to the Growth of the Biomarker Clinical Phase Outsourcing Services Market’s Growth?

The biomarker clinical phase outsourcing services market is forecasted to grow due to the rising number of clinical trials. These trials involve human participants and are designed to gauge the safety and efficacy of novel medical treatments, interventions or diagnostic procedures. The growth in clinical trials can be attributed to progress in medical research, an escalating prevalence of chronic diseases, rising investment from both public and private sectors, and an increasing demand for innovative treatment methods and therapies. Biomarker discovery, validation, and analysis are areas often specialised by outsourcing providers. This specialist knowledge can help in improving the quality and trustworthiness of the biomarker data gathered throughout the trial. For example, the United States National Library of Medicine pointed out in May 2023 that registered clinical trials had risen from 399,499 in 2022 to 437,533 across all 50 states and in 221 other countries. It was also highlighted that the United States had recorded 140,492 studies (31%), while 241,498 studies (53%) were registered outside the U.S. Therefore, the increasing number of clinical trials is projected to stimulate the growth of the biomarker clinical phase outsourcing services market.

Explore Comprehensive Insights Into The Global Biomarker Clinical Phase Outsourcing Services Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are:

• Thermo Fisher Scientific Inc.

• Labcorp Drug Development Inc.

• ICON plc

• Eurofins Scientific SE

• WuXi AppTec Co. Ltd.

What Are the Key Emerging Trends in the Biomarker Clinical Phase Outsourcing Services Market for the Next Decade?

Top-tier companies in the biomarker clinical phase outsourcing services sector are working on the advancement of high-throughput flow cytometry and ELISpot testing techniques to achieve a competitive edge in the market. These techniques are used for biomarker analysis, offering swift and accurate evaluations of immune responses and cellular markers. For example, in November 2022, Celerion Inc., a biotechnology outsourcing services firm based in the US, broadened its portfolio to incorporate GLP/GCP-compliant molecular and cell biology testing. This strategic step is designed to boost Celerion’s abilities in aiding clients all through the drug development cycle, from early clinical studies to regulatory filings. By incorporating GLP/GCP-compliant molecular and cell biology tests, like pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis, Celerion is now able to provide a broader range of services. This expansion equips Celerion to help clients in generating superior quality data that complies with regulatory standards, ultimately accelerating the creation of new pharmaceuticals.

Secure Your Global Biomarker Clinical Phase Outsourcing Services Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

How Are the Key Segments of the Biomarker Clinical Phase Outsourcing Services Market Impacting Its Expansion and Revenue Streams?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

Which Regions Are Making a Mark in the Biomarker Clinical Phase Outsourcing Services Market Growth?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2023. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Does the Definition of the Biomarker Clinical Phase Outsourcing Services Market Include?

Biomarker clinical phase outsourcing services refer to the practice of contracting specialized firms or organizations to conduct various aspects of clinical trials related to biomarkers. Biomarkers are measurable indicators of biological states or conditions, often used in medical research and clinical trials to assess the effectiveness or safety of a drug or treatment.

Browse Through More Similar Reports By The Business Research Company:

Bioanalytical Testing Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioanalytical-testing-services-global-market-report

Single-Use Bio Reactors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/singleuse-bioreactors-global-market-report

Bioadhesives Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioadhesives-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: